MedTrace Logo

Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy

NCT00107549 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-11-01

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of two recombinant HIV vaccines in HIV infected young adults on stable anti-HIV therapy.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])

Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4

BIOLOGICAL

rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])

Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Coleen K. Cunningham, MD · Pediatric Infectious Diseases, Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2009-02-28

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00107549 on ClinicalTrials.gov